Compare FBIO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBIO | ADCT |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | Switzerland |
| Employees | 78 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | 136.1M |
| IPO Year | N/A | 2019 |
| Metric | FBIO | ADCT |
|---|---|---|
| Price | $3.37 | $1.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $17.00 | $7.75 |
| AVG Volume (30 Days) | 611.0K | ★ 1.5M |
| Earning Date | 05-15-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | $55.22 | N/A |
| Revenue Next Year | $40.55 | $66.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $1.77 | $0.78 |
| 52 Week High | $4.53 | $4.98 |
| Indicator | FBIO | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 43.09 |
| Support Level | $3.28 | $0.78 |
| Resistance Level | $3.80 | $1.44 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 59.46 | 75.00 |
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).